A detailed history of Voya Investment Management LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 23,699 shares of VERV stock, worth $114,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,699
Previous 23,544 0.66%
Holding current value
$114,940
Previous $114,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $682 - $1,218
155 Added 0.66%
23,699 $114,000
Q2 2024

Aug 14, 2024

BUY
$4.76 - $12.79 $13,342 - $35,850
2,803 Added 13.51%
23,544 $114,000
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $454 - $754
42 Added 0.2%
20,741 $275,000
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $2,669 - $5,647
302 Added 1.48%
20,699 $288,000
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $4,282 - $7,807
375 Added 1.87%
20,397 $270,000
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $27,813 - $41,491
2,085 Added 11.62%
20,022 $375,000
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $10,692 - $24,379
599 Added 3.45%
17,937 $347,000
Q3 2022

Mar 03, 2023

SELL
$15.63 - $41.49 $9,362 - $24,852
-599 Reduced 3.34%
17,338 $595,000
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $57,674 - $153,098
3,690 Added 27.04%
17,338 $596,000
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $152,038 - $316,224
13,648 New
13,648 $209,000
Q1 2022

May 16, 2022

SELL
$20.92 - $39.36 $127,068 - $239,072
-6,074 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $6,451 - $11,073
-202 Reduced 3.22%
6,074 $224,000
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $288,696 - $464,361
6,276 New
6,276 $295,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.